- Home
- RSVR vs GOSS Comparison
RSVR vs GOSS Comparison
Compare RSVR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- GOSS
- Stock Information
- Founded
- RSVR 2007
- GOSS 2015
- Country
- RSVR United States
- GOSS United States
- Employees
- RSVR N/A
- GOSS N/A
- Industry
- RSVR Movies/Entertainment
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- RSVR Consumer Discretionary
- GOSS Health Care
- Exchange
- RSVR Nasdaq
- GOSS Nasdaq
- Market Cap
- RSVR 498.2M
- GOSS 501.2M
- IPO Year
- RSVR N/A
- GOSS 2019
- Fundamental
- Price
- RSVR $7.34
- GOSS $2.37
- Analyst Decision
- RSVR Strong Buy
- GOSS Strong Buy
- Analyst Count
- RSVR 1
- GOSS 6
- Target Price
- RSVR $11.50
- GOSS $8.60
- AVG Volume (30 Days)
- RSVR 61.8K
- GOSS 2.8M
- Earning Date
- RSVR 11-04-2025
- GOSS 11-05-2025
- Dividend Yield
- RSVR N/A
- GOSS N/A
- EPS Growth
- RSVR N/A
- GOSS N/A
- EPS
- RSVR 0.15
- GOSS N/A
- Revenue
- RSVR $166,320,844.00
- GOSS $44,051,000.00
- Revenue This Year
- RSVR $7.17
- GOSS N/A
- Revenue Next Year
- RSVR $5.00
- GOSS $16.11
- P/E Ratio
- RSVR $50.10
- GOSS N/A
- Revenue Growth
- RSVR 11.17
- GOSS N/A
- 52 Week Low
- RSVR $6.56
- GOSS $0.66
- 52 Week High
- RSVR $9.83
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- RSVR 43.38
- GOSS 48.68
- Support Level
- RSVR $7.28
- GOSS $2.20
- Resistance Level
- RSVR $7.57
- GOSS $2.52
- Average True Range (ATR)
- RSVR 0.22
- GOSS 0.15
- MACD
- RSVR 0.00
- GOSS 0.01
- Stochastic Oscillator
- RSVR 27.87
- GOSS 63.95
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.